AbbVie lowers 2024 adjusted EPS guidance to $10.61-$10.81 on $937M IPR&D charge

AbbVie Inc.

2024-Q2 EPS reported $1.53 revenue$26,772,000,000

Preliminary Q2 2024 acquired IPR&D and milestones expense of $937 million pre-tax.
GAAP and adjusted non-GAAP diluted EPS each reduced by $0.52 in Q2.
Q2 2024 adjusted diluted EPS guidance set at $2.53-$2.57.
Full-year 2024 adjusted diluted EPS guidance lowered to $10.61-$10.81 from $11.13-$11.33.
Guidance excludes any future IPR&D expense beyond Q2; final Q2 results subject to closing procedures.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.